| FSOPX | FSSNX | FSOPX / FSSNX | |
| Total Expense Ratio | 0.00 | 0.03 | - |
| Annual Report Gross Expense Ratio | 0.00 | 0.03 | - |
| Fund Existence | 19 years | 14 years | - |
| Gain YTD | 7.337 | 6.434 | 114% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 4.85B | 29.7B | 16% |
| Annual Yield % from dividends | 0.97 | 1.03 | 95% |
| Returns for 1 year | 18.38 | 18.62 | 99% |
| Returns for 3 years | 38.87 | 39.32 | 99% |
| Returns for 5 years | 6.33 | 25.49 | 25% |
| Returns for 10 years | 74.41 | 169.89 | 44% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| ZEMAX | 14.52 | 0.19 | +1.33% |
| American Beacon Ninety One Emr Mkts Eq Y | |||
| BIIEX | 28.95 | 0.05 | +0.17% |
| Brandes International Equity I | |||
| RYLDX | 206.82 | -1.49 | -0.72% |
| Rydex Dow 2x Strategy A | |||
| BMDSX | 17.25 | -0.17 | -0.98% |
| Baird Mid Cap Growth Investor | |||
| THISX | 82.61 | -0.84 | -1.01% |
| T. Rowe Price Health Sciences I | |||